There are indirect evidences showed that there is an association between neutropenia and some of the medications such as Anti-thymocyte Globulin (ATG), Mycophenolic acid (MPA) and Tacrolimus (TAC) that are use for kidney transplant patients. It is evidenced that are driven upon reducing dose or holding these medications. The prolonged and severe neutropenia can lead to serious infections and allograft rejection. A retrospective cohort study where patients had been tackled over six months post kidney transplantation. The 81 patients who had transplantation between January 2014 and December 2014 were identified and followed up using hospital system and patients medical records. The incidence of neutropenia was 11.11%. The findings show an association between neutropenia post kidney transplant and some factors including: female gender and the use of immunosuppressant medications, like MPA (P>0.05). Eighty one patients were tackled retrospectively for 6 months. The incidence of neutropenia were 11.11%. TAC and MPA were used in all of patients. This study claimed that these medications might increase the risk of neutropenia post kidney transplant; P<0.05. The findings of the present study indicate the holding MPA and using G-CSF is significantly effective to accelerate the recovery of neutropenia. The incidence of neutropenia in this study was relatively high post kidney transplant with female gender and MPA alone or in combination with TAC being potentially associated factors with neutropenia.
 

Download Full Text - PDF